AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Teva Pharmaceutical Industries Ltd. Director's Dealing 2023

Jun 20, 2023

7082_dirs_2023-06-20_c65e114b-8ada-47cb-8e6d-1a7997ed4788.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2023-06-15

Reporting Person: BARER SOL J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-15	Restricted Share Units	$	A	37598	Acquired		Ordinary Shares (37598)	Direct

Footnotes

F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.

F2: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024.

F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.